13 unknown, 5 completed. 6 Phase 4, 3 Not applicable, 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Unknown 4, Completed 2 |
| Not applicable | 3 | Unknown 2, Completed 1 |
| Phase 3 | 3 | Unknown 3 |
| Phase 2 | 1 | Unknown 1 |
Follow Kobe University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 ) Empagliflozin Tablets - Insulin Resistance - Type A, Insulin Resistance - Type B | Phase 3 | Unknown | Kobe University | 8 | 2020-02-01 | 2021-06-03 |
| A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance Empagliflozin Tablets - Insulin Resistance - Type A, Insulin Resistance - Type B | Phase 3 | Unknown | Kobe University | 8 | 2019-09-01 | 2021-03-03 |
| Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO] EPA and rosuvastatin, High dose rosuvastatin - Coronary Artery Disease, Angina Pectoris | Phase 4 | Unknown | Kobe University | 75 | 2018-09-17 | 2018-09-18 |
| Evaluation of Fractional Flow Reserve Calculated by Computed Tomography Coronary Angiography in Patients Undergoing TAVR iFR / FFR measurement - Aortic Valve Stenosis, Coronary Artery Disease | Not applicable | Unknown | Kobe University | 25 | 2018-09-13 | 2018-09-13 |
| Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily, Rosuvastatin calcium10mg - Coronary Artery Disease, Angina Pectoris | Phase 4 | Unknown | Kobe University | 30 | 2018-04-01 | 2018-08-31 |
| To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy Alirocumab - Coronary Artery Disease Progression | Unknown | Kobe University | 31 | 2017-12-18 | 2018-05-30 | |
| The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography Alirocumab - Coronary Artery Disease, Thin-cap fIbroatheroma | Phase 4 | Unknown | Kobe University | 24 | 2017-08-23 | 2018-11-14 |
| Comparisons of Morphological Measurement Between Coronary Computed Tomography and Optical Coherence Tomography data collection, non-intervention - Coronary Artery Disease | Completed | Kobe University | 72 | 2016-07-01 | 2017-01-13 | |
| Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent CoCr-EES - Coronary Artery Disease | Not applicable | Unknown | Kobe University | 104 | 2014-01-01 | 2017-10-18 |
| Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy NPC-14, Placebo - Muscular Dystrophy, Duchenne | Phase 2 | Unknown | Kobe University | 21 | 2013-08-01 | 2015-09-03 |
| Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial EPA and high dose rosuvastatin, Standard dose rosuvastatin - Coronary Artery Disease Progression | Phase 4 | Completed | Kobe University | 50 | 2013-07-26 | 2018-01-09 |
| Relation Among Shear Stress Distribution, Stent Design, and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Promus element, Xience prime, and Nobori - Coronary Heart Disease | Phase 4 | Unknown | Kobe University | 30 | 2013-02-01 | 2013-09-13 |
| Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography Coronary Heart Disease | Unknown | Kobe University | 40 | 2012-09-01 | 2013-09-09 | |
| A Prospective Randomized Controlled Multicenter Trial of Delayed Gastric Emptying (DGE) After Pancreaticoduodenectomy Evaluating by Gastrointestinal Reconstruction Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy, Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy - Postprocedural Delayed Gastric Emptying | Phase 3 | Unknown | Kobe University | 240 | 2011-11-01 | 2015-04-01 |
| Relation Among HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization neoatherosclerosis - Coronary Artery Disease Progression | Completed | Kobe University | 181 | 2011-05-01 | 2018-05-30 | |
| Carotid Artery Stenting With Cilostazol Addition for Restenosis Cilostazol or Non-Cilostazol - In-stent Restenosis After Carotid Artery Stenting | Not applicable | Completed | Kobe City General Hospital | 707 | 2010-12-01 | 2019-10-16 |
| Quality of Sleep in Patients With Rheumatoid Arthritis diazepam, melatonin - Rheumatoid Arthritis | Unknown | Kobe University | 1000 | 2006-02-01 | 2009-03-16 | |
| Protective Effect of EPA on Cardiovascular Events Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM) - Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease | Phase 4 | Completed | Kobe University | 18000 | 1996-11-01 | 2015-11-20 |
Coronary Artery Disease (7) · Angina Pectoris (2) · Coronary Disease (2) · Diabetes Mellitus (2) · Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans (2) · Diabetes Mellitus, Lipoatrophic (2) · Insulin Resistance (2) · Metabolic Syndrome (2) · Angina, Unstable (1) · Aortic Valve Stenosis (1) · Arthritis, Rheumatoid (1) · Carotid Artery Diseases (1) · Death, Sudden, Cardiac (1) · Gastroparesis (1) · Muscular Dystrophy, Duchenne (1)
alirocumab (3) · Rosuvastatin Calcium (2) · empagliflozin (2) · Cilostazol (1) · Data Collection (1) · Diazepam (1) · Eicosapentaenoic Acid (1) · Melatonin (1) · Population Groups (1) · arbekacin (1)
Japan (16)
Wataru Ogawa (2) · Hirofumi Komaki, MD, PhD (1) · Hiromasa Otake, M.D, Ph,D (1) · Hiromasa Otake, M.D., Ph.D (1) · Hiromasa Otake, MD, PhD (1) · Hiromasa Otake, PhD (1) · Hiromasa Otake, ph.D (1) · Hiroshi Yamagami, MD, PhD (1) · Mitsuhiro Yokoyama, MD, PhD. (1) · Nobuyuki Sakai, MD, DMSc (1) · Shunichi Shiozawa, MD, PhD (1) · Toshiro Shinke (1) · Toshiro Shinke, MD, PhD (1) · Yasuhiro Takeshima, MD, PhD (1) · Yonson Ku, MD (1)
PMID 17398308, PMID 18451347, PMID 18667204, PMID 19423946, PMID 19447387, PMID 20145342, PMID 20484828, PMID 30579806, PMID 32773628, PMID 38216831, PMID 39585936